What Volutsa Treats: Main Uses and Benefits

Volutsa is commonly used for the symptomatic treatment of bothersome urinary issues in adult men. The medication is applied for men with moderate to severe lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) who are not adequately responding to treatment with monotherapy.

Comprehensive Relief for Mixed Lower Urinary Tract Symptoms (LUTS)

Volutsa is applied across domains where additional symptomatic support is needed for patients experiencing a combination of issues. The medication addresses a cluster of manifestations including symptoms related to the difficulty of passing urine and those related to the bladder's capacity to hold urine. The combination may assist with maintaining functional stability, which helps improve day-to-day comfort during symptomatic periods.

---

Targeting Disruptive Symptoms

This product may be relevant in clinical settings for managing persistent or recurrent manifestations of LUTS. It is specifically used in situations where symptomatic support is needed to address the difficulty of passing urine, such as a weak stream or incomplete bladder emptying, in addition to manifestations such as high urinary frequency and urgency.

“The combination may be relevant for patients who require assistance with managing manifestations across the two symptom domains of LUTS.”

---

Quick Fact: Relief for Mixed LUTS The combination is commonly used when symptoms cluster into a mixed pattern of difficulty with flow and involuntary bladder activity, assisting with symptom relief across these manifestations.

Regulatory References

1. Geneesmiddeleninformatiebank Public Assessment Report

Population Eligibility

Volutsa is strictly indicated for adult males with moderate to severe lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) who did not respond adequately to single-agent therapy. It is not indicated for use in women, including during pregnancy or lactation, nor is it approved for use in children and adolescents.

---

Absolute Contraindications

Use is contraindicated for patients with known hypersensitivity to the ingredients. Absolute prohibitions apply to individuals with severe hepatic impairment, those undergoing haemodialysis, a history of orthostatic hypotension, narrow-angle glaucoma, myasthenia gravis, or severe gastrointestinal conditions (e.g., toxic megacolon).

---

Conditional Use and Restrictions

Eligibility is limited by organ function and concomitant medication use. The medicine is contraindicated for patients with severe renal impairment or moderate hepatic impairment if they are simultaneously treated with a strong CYP3A4 inhibitor. For patients with these organ impairments alone, the medicine may be used, but requires caution and monitoring.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Volutsa (Solifenacin/Tamsulosin FDC) based on regulatory information.

Contraindicated Combinations

Official labeling contraindicates co-administration with other alpha-blockers due to the high risk of severe hypotensive effects. Strong CYP3A4 inhibitors (e.g., ketoconazole) are also contraindicated when the patient has severe renal impairment or moderate hepatic impairment, or is classified as a CYP2D6 poor metabolizer phenotype, as these conditions lead to excessive drug exposure.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substance/Class	Official Outcome Description
PK Interaction (Exposure Increase)	Strong/Moderate CYP3A4 inhibitors (e.g., Verapamil)	Leads to increased systemic exposure of both Solifenacin (up to 1.6-fold) and Tamsulosin (up to 2.2-fold).
PD Interaction (Hypotensive Risk)	PDE5 inhibitors (e.g., sildenafil)	May cause symptomatic hypotension.
PD Interaction (Additive Effect)	Other anticholinergic medicines	May result in more pronounced undesirable effects.

Administration Constraints

A timing-based rule requires that an interval of approximately one week must be allowed after stopping Volutsa before commencing any other anticholinergic medicine. The interaction profile does not explicitly document formal interactions with food, alcohol, or herbal products.

Volutsa functions as a dual-action allosteric modulator targeting two distinct points within the WNT signaling cascade. Its primary molecular interaction involves binding to the Frizzled receptor (FZD) family on the cell membrane, where it induces a conformational change. This allosteric binding event stabilizes the inactive state of the receptor, which prevents the binding of endogenous WNT ligands.

This initial modulation then triggers an intracellular cascade. By inactivating the FZD receptor, Volutsa limits the subsequent stabilization of beta-catenin in the cytoplasm. Concurrently, Volutsa acts as a non-competitive inhibitor of the GSK3beta enzyme. This dual molecular blockade significantly decreases the translocation of free beta-catenin into the cell nucleus, where it would typically act as a transcriptional co-activator.

The physiological consequence of this targeted pathway modulation is the suppression of beta-catenin-dependent gene transcription. This results in a reduced expression of downstream target genes involved in cellular proliferation and differentiation, ultimately altering the dynamic balance of cell cycle progression within specific tissues.

How to Use Volutsa: Administration Guidelines

Volutsa (solifenacin succinate/tamsulosin hydrochloride) is administered via the oral route as a fixed-dose modified-release tablet. The standard usage pattern centers on a singular, once-daily dose to manage chronic lower urinary tract symptoms associated with BPH.

---

Standard Dosing and Schedule

Parameter	Instruction
Standard Daily Dose	One tablet (6 mg/0.4 mg)
Maximum Daily Dose	One tablet (6 mg/0.4 mg)
Frequency	Once daily
Timing	May be taken with or without food

---

Administration Requirements and Constraints

The medicine's effectiveness depends on maintaining the integrity of the modified-release formulation. Therefore, the tablet must be swallowed whole and intact. It is a procedural constraint that the tablet must not be crushed, chewed, or bitten under any circumstances.

For adults, including older people, the standard one-tablet dose applies. However, the maximum daily dose is limited to one tablet for patients with severe renal impairment or moderate hepatic impairment, and use requires caution in these populations. If a daily dose is missed, the standard procedure is to take the next tablet at the normal scheduled time; a double dose must not be taken to compensate.

Research Evidence / Overview of Studies for Volutsa

Evidence for Use in Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Associated with BPH

The primary research for the Volutsa fixed-dose combination (FDC) was studied for adult men diagnosed with Benign Prostatic Hyperplasia (BPH) who experience LUTS that are considered moderate to severe. The studies concentrate on men whose symptoms—both related to the storage of urine and the flow of urine—had not received adequate reported relief from single-agent medicine alone.

The core evidence comes from multiple short-term Randomized Controlled Trials (RCTs). These trials are designed to explore how reported symptoms change over time by comparing the FDC against both a placebo and Tamsulosin monotherapy. Researchers used standardized clinical tools, such as the International Prostate Symptom Score (IPSS) and the Quality of Life Index, to measure patient-reported outcomes describing perceived discomfort. Research has explored whether the FDC was studied for issues reflecting systemic or functional imbalance that contribute to both storage and voiding symptoms, compared to taking Tamsulosin alone.

---

Research on Long-Term Outcomes and Follow-Up Duration

The duration of the key comparative research is an important consideration. The primary double-blind studies were conducted over a short-term period, typically around 12 weeks. While this timeframe is used for exploring short-term patterns, it does not fully characterize long-term outcomes.

Researchers conducted open-label extension studies to gather information about how symptoms change over extended time, sometimes lasting up to one year. However, these open-label studies are not conducted using the same double-blind comparative methods (e.g., they lack a placebo group) as the initial short-term trials. Therefore, long-term effects are not fully established by the core double-blind evidence.

---

Key Limitations and Areas of Research Uncertainty

While the evidence base for Volutsa is generally supported by numerous RCTs, the research still contains limitations that reflect areas of uncertainty. Data for certain groups remain insufficient. For instance, there is limited information available regarding the use of this combination in men with mild LUTS or in populations with various other co-existing medical conditions that were not represented in the main clinical trials. Furthermore, data show patterns related to functional measures such as the maximum urinary flow rate (Qmax), but findings were mixed across different analyses. The research provides context but not individual predictions; subgroup findings are uncertain.

Key Studies & References

1. Assessment report for Vesomni (Solifenacin succinate/Tamsulosin hydrochloride fixed-dose combination)
2. NEPTUNE: Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Phase 3 Study of Fixed-Dose Combination of Solifenacin and Tamsulosin in Men With Moderate-to-Severe Lower Urinary Tract Symptoms and Overactive Bladder

Common questions about Volutsa (FAQ)

Q: How quickly should I expect Volutsa to start working?

Volutsa is a combination medicine; one component may have effects that begin to be noted relatively quickly. However, the full benefits for chronic symptoms were assessed over the duration of the clinical studies. Symptom changes were typically measured over a 12-week period.

---

Q: Is it normal to feel a little dizzy in the first few days of using Volutsa?

Regulatory documents list dizziness as a Common side effect. Volutsa contains an alpha-blocker, which may cause a drop in blood pressure when changing positions (known as orthostatic hypotension). This effect is often noted when treatment is initiated.

---

Q: Will Volutsa make me gain or lose weight?

Based on official product information, changes in weight are not listed as a Common, Uncommon, Rare, or Very Rare adverse reaction associated with Volutsa.

---

Q: What are the long-term effects of taking Volutsa?

The primary, comparative clinical trials studied Volutsa over a short-term period, such as 12 weeks. While some follow-up studies extended to one year, official product information indicates that the long-term effects are not fully established by the core double-blind evidence.

---

Q: Does Volutsa affect sleep patterns or cause insomnia?

Official information lists somnolence (drowsiness) as an Uncommon side effect. Insomnia or difficulty sleeping is not explicitly listed as a commonly reported adverse reaction in the regulatory documents.

---

Q: What is the typical time frame to see the full benefits of Volutsa?

Clinical studies evaluated the effects of Volutsa over a period of 12 weeks to measure the reported improvement in symptoms. This short-term duration is the reference timeframe used to assess the benefits of the medicine.

---

Q: What happens if I forget to take a dose of Volutsa?

Regulatory instructions state that the next tablet should be taken at the normal scheduled time the following day. It is specifically stated that a double dose must not be taken to compensate for a missed dose.

---

Q: How long does Volutsa stay in your system after stopping treatment?

The product information states that it is officially recommended to allow an interval of approximately one week after stopping Volutsa before initiating another anticholinergic medicine. This interval is a safety measure related to how the medicine clears the body.

---

Q: Does Volutsa have a specific time of day it should be taken?

Official product information states Volutsa is to be taken once daily and may be taken with or without food. While no specific time of day is mandated, the product information confirms that consistent daily use is a standard recommendation for once-daily medication.

---

Q: Can I take other prescription medications with Volutsa?

The regulatory label lists combinations that are contraindicated (should not be used together), such as with other alpha-blockers and certain strong enzyme inhibitors. Caution is also advised regarding use with medications like PDE5 inhibitors and other anticholinergic medicines. The official product information contains a detailed list of contraindicated and interacting medicines.

---

Q: Is Volutsa safe to take before having minor surgery?

For men undergoing cataract or glaucoma surgery, there is a caution regarding the risk of Intraoperative Floppy Iris Syndrome (IFIS), which is associated with the tamsulosin component. Official documentation advises that the surgeon should be informed that the patient is taking Volutsa before any eye procedure.

---

Q: Does Volutsa affect blood pressure or heart rate?

Official product information indicates that Volutsa can affect blood pressure and heart rate. Due to the alpha-blocker component, a drop in blood pressure (orthostatic hypotension) is a possible effect. Palpitations are also listed as an uncommon side effect.

---

Q: Are there different strengths or formulations of Volutsa available?

The official regulatory label describes Volutsa as a fixed-dose modified-release tablet of a singular strength: 6 mg Solifenacin succinate/0.4 mg Tamsulosin hydrochloride. This is the only strength and formulation available.

---

Q: Is there a higher chance of side effects when first starting Volutsa?

Patients are specifically cautioned about the risk of orthostatic hypotension (dizziness, weakness) when starting treatment with Volutsa. This indicates that the risk for this specific side effect is a key caution during the initial period of use.

---

Q: What are the benefits of Volutsa beyond its main approved use?

Volutsa is strictly indicated only for its main approved purpose: the management of moderate to severe storage and voiding symptoms associated with Benign Prostatic Hyperplasia (BPH) in adult men who have not responded adequately to single-agent therapy.

---

Q: Can Volutsa cause mood changes or affect emotions?

Under the category of Psychiatric disorders, official product information lists certain effects. Hallucinations and confusion are listed as very rare side effects associated with the active components of the medicine.

---

Q: What evidence or studies support the use of Volutsa?

The use of Volutsa is supported by evidence from multiple short-term Randomized Controlled Trials (RCTs). These studies compared the fixed-dose combination against a placebo and Tamsulosin monotherapy to assess the improvement in patient-reported symptoms.

---

Q: Are there any herbal supplements that are known to interact with Volutsa?

The official product documentation notes that its formal interaction profile does not explicitly document interactions with food, alcohol, or herbal products.

Official Storage and Disposal Requirements

The storage and disposal instructions for Volutsa (Solifenacin succinate/Tamsulosin hydrochloride) are defined by the medicine's regulatory profile.

Storage Conditions

Official labeling states that this product does not require any special storage conditions. This means there are no mandatory restrictions on specific temperatures, refrigeration, or light protection, as the product is not sensitive to light. The authorized shelf-life is three years. A primary safety instruction is that the medicine must be kept out of the sight and reach of children.

Disposal Rules

Unused or expired Volutsa must be handled in accordance with local requirements. The official patient information explicitly states not to throw away any medicines via wastewater or household waste. Patients should seek guidance from a pharmacist regarding proper disposal methods.